RxDoctor Payments Data

Suman Patel, MD

Internal Medicine · van Nuys, CANPI 1437225174

Payments from drug & device makers

$246in general payments, 2019–2025

Across 12 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$84
  • Philips North America LLC$62
  • Acadia Pharmaceuticals Inc$47
  • Lundbeck LLC$28
  • Sunovion Pharmaceuticals Inc.$26

What the payments were for

  • Food & beverage$246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$246 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$157,754
Medicare patients
226
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban550$185,892
Invega SustennaPaliperidone Palmitate26$67,584
OtezlaApremilast12$60,748
IngrezzaValbenazine Tosylate12$43,298
NplateRomiplostim16$42,516
Pantoprazole Sodium530$41,735
SantylCollagenase Clostridium Hist.19$40,144
EntrestoSacubitril/Valsartan68$31,006
XifaxanRifaximin24$29,225
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate17$26,527
OzempicSemaglutide26$25,513
ProcritEpoetin Alfa29$24,910
Austedo XrDeutetrabenazine11$24,873
NuedextaDextromethorphan Hbr/Quinidine28$21,181
TradjentaLinagliptin73$20,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$84$13,97025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →